On Thursday, Bristol-Myers Squibb said it was halting development of a drug known as BMS-986094 and designed to treat Hepatitis C, after nine patients in a mid-stage clinical trial were hospitalized, one of whom later died from heart failure. Though the connection between the drug trial and heart failure is not yet confirmed, the company issued a statement last night saying development would stop immediately. The turn of events is a huge setback for the company, who paid $2.5 billion in January to acquire Inhibitex, who was developing the drug that became known as BMS-986094. Competing pharmaceuticals companies, including Idenix Pharmaceuticals and Gilead Sciences are also chasing a drug to treat Hepatitis C, a viral infection that can cause liver scarring and liver cancer.
A House Medicare for All hearing led to talk about making doctors salaried government employees.
If your sales are soft, here are ideas about how to fix that.
One of the weak performers was voluntary dental insurance.
Sponsored by FTJ | FundChoice
A full-service solution that helps you improve your process and client relationships sounds great, but you must be able to determine what will best help your firm grow.
Sponsored by Smarsh
New communication tools can open up your firm to risk and prohibition is not prevention. Learn five key practices you should implement now.
Don’t miss crucial news and insights you need to make informed investment advisory decisions. Join ThinkAdvisor.com now!
- Free unlimited access to ThinkAdvisor.com which provides advisors, like you, with comprehensive coverage of the products, services and trends necessary to guide your clients in making critical wealth, health and life decisions.
- Exclusive discounts on ALM and ThinkAdvisor events.
- Access to other award-winning ALM websites including TreasuryandRisk.com and Law.com.
Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.